Results 81 to 90 of about 1,039,827 (235)
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.The graphical abstract represents the underlying neuroprotective potential of ICS II against Alzheimer's disease, Cerebral ischemia and Parkinson disease. ICS II downregulates ROS production, inflammation, mitochondrial dysfunction and apoptosis along with regulating their key signalling pathways.
Ashutosh Solanki +4 more
wiley +1 more source
The making of CorDis: corpus compilation and mark-up
, 2007 In the present paper we set out to discuss the role of mark-up in a large XML-annotated, TEI-conformant corpus. The corpus in question – called CorDis – is a large multimodal, multigenre collection of texts representing a significant portion of the ...
VENUTI, MARCO, L. Cirillo, A. Marchi
core
NEUROPATHOLOGICAL CHANGES IN THE PDAPP TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE [PDF]
Acta Medica Iranica, 2005 Alzheimer’s disease (AD) is a uniquely human disorder. Although the pathogenesis of AD is not fully understood, growing evidence indicates that the deposition of beta-amyloid (Aβ) and the local reactions of various cell types to this protein play major ...
P. Pasbakhsh +1 more
doaj +1 more source
New Studies of the Anatomy and Pathology of the Corpus Striatum [PDF]
The Journal of Nervous and Mental Disease, 1921 n ...
openaire +1 more source
Slovenian parliamentary corpus ParlaMeter-sl 1.0 [PDF]
, 2019 The ParlaMeter-sl corpus contains minutes of the National Assembly of the Republic of Slovenia and currently covers its VIIth mandate (2014-08-01 to 2018-06-22).
Ljubešić, Nikola +2 more
core
Frontiers in Cellular Neuroscience, 2019 ATP-binding cassette (ABC) transporters prevent the access of pharmacological compounds to the ischemic brain, thereby impeding the efficacy of stroke therapies.
Daniel Manrique-Castano +7 more
doaj +1 more source
Movement Disorders Clinical Practice, Volume 13, Issue 9, Page 2216-2224, September 2026.Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse +224 more
wiley +1 more source
Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Movement Disorders Clinical Practice, Volume 13, Issue 9, Page 2093-2103, September 2026.Abstract Background The transplantation of homogenous cells has emerged as an investigational strategy for Parkinson's disease (PD), offering an alternative to symptomatic treatment. Objective We performed a systematic review and meta‐analysis to assess its clinical efficacy and safety.
Nolan Reinisch +4 more
wiley +1 more source
ChemistryOpen, Volume 15, Issue 9, September 2026.Neurological disorders (NDs) are characterized by substantial loss of specific neurons, with Alzheimer's and Parkinson's diseases being the most frequent NDs and nearly 99% of all “foreign substances” are prohibited from entering the brain by the blood‐brain barrier (BBB) and the blood‐cerebrospinal fluid barrier (CFB).
Nnamdi Ikemefuna Okafor +3 more
wiley +1 more source
Synapse, Volume 80, Issue 5, September 2026.[18F]Nifene, a PET imaging probe for α4β2* nicotinic acetylcholine receptors, was used to discretely measure changes in hippocampus (HP) and subiculum (SUB) of postmortem Parkinson's disease (PD) cases compared to cognitively normal (CN) cases. Significant increased [18F]nifene binding in PD was observed.
Jogeshwar Mukherjee +5 more
wiley +1 more source